Found 34 clinical trials
Study of DC-CIK Combined With Chemotherapy for Advanced Solid Tumor
Combinations of Dendritic cell-activated cytokine-induced killer cell (DC-CIK) With chemotherapy treatment may enhance the immune response and stop cancer cells from growing.
- 0 views
- 19 Feb, 2024
Dose-escalation Study of APG-1387 and Toripalimab in Solid Tumors
An ascending dose study in patients with solid tumors to evaluate the safety, tolerability, pharmacodynamics and efficacy of APG-1387 in combination with toripalimab. A phase II study of 3 cohorts will be included.
- 0 views
- 19 Feb, 2024
PTX-35 in Patients With Advanced Solid Tumors
A Phase I, First-in-Human, Dose-Escalation Study to Evaluate the Safety of the Monoclonal Antibody PTX-35 in Patients with Advanced Solid Tumors Refractory to Standard of Care
- 0 views
- 19 Feb, 2024
A Trial of ZL-1201 in Subjects With Advanced Cancer
First in Human, Phase I Trial of Anti-CD47 Antibody ZL-1201 in Subjects with Advanced Cancer
- 0 views
- 19 Feb, 2024
CyPep-1 Injections in Cancer Inducing Lymphocyte Infiltrate Accumulations
This Phase I/IIa trial is designed to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of CyPep-1 when administered directly into malignant tumors. Additionally, the trial will monitor anti-tumor effects on both injected lesions and distant non-injected deposits.
- 0 views
- 19 Feb, 2024
MTD Safety and Efficacy of NYH817G and NYH100P in Monotherapy and Combination in Patients With Advanced Solid Tumors
The objectives of this study are: Part 1: To assess the MTD, safety and efficacy of each NYH817G and NYH100P in monotherapy in patients with advanced solid tumors who have failed approved standard therapies. To assess the PK properties and the preliminary effectiveness of monotherapy of NYH817G and NYH100P. Part …
- 0 views
- 19 Feb, 2024
Study of AMG 650 in Adult Participants With Advanced Solid Tumors
To evaluate the safety and tolerability of AMG 650 in adult participants and to determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D).
- 0 views
- 19 Feb, 2024
A Study to Assess the Safety Pharmacokinetics and Anti Tumor Activity of UCB6114 Administered Intravenously to Participants With Advanced Solid Tumors
The purpose of the study is to characterize the safety and pharmacokinetic (PK) profile of UCB6114.
- 0 views
- 19 Feb, 2024
A Study to Evaluate the Tolerance Efficacy and Pharmacokinetics of TQB3558 Tablets
This is a study to evaluate the maximum tolerated dose (MTD) , occurrence of all adverse events (AE) and serious adverse events (SAE) , pharmacokinetic parameters and antitumor effect of TQB3558 tablets in Chinese adult patients with advanced solid tumors .The study is divided into phase Ia and phase Ib. …
- 0 views
- 19 Feb, 2024
Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors
IMC-F106C is an immune-mobilizing T cell receptor against cancer (ImmTAC ) designed for the treatment of cancers positive for the tumor-associated antigen PRAME. This is a first-in-human trial designed to evaluate the safety and efficacy of IMC-F106C in adult patients who have the appropriate HLA-A2 tissue marker and whose cancer …
- 0 views
- 19 Feb, 2024